Review

Alcohol, Drinking Pattern, and Chronic Disease

María Barbería-Latasa \(^1\), Alfredo Gea \(^{1,2,3,*}\) and Miguel A. Martínez-González \(^{1,2,3}\)

\(^1\) Department of Preventive Medicine and Public Health, University of Navarra, 31008 Pamplona, Spain; mbarberia.3@unav.es (M.B.-L.); mamartinez@unav.es (M.A.M.-G.)
\(^2\) IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain
\(^3\) Biomedical Research Network Center for Pathophysiology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, 28029 Madrid, Spain

* Correspondence: ageas@unav.es

Abstract: This review discusses the inconsistent recommendations on alcohol consumption and its association with chronic disease, highlighting the need for an evidence-based consensus. Alcohol is an addictive substance consumed worldwide, especially in European countries. Recommendations on alcohol consumption are controversial. On one hand, many nonrandomized studies defend that moderate consumption has a beneficial cardiovascular effect or a lower risk of all-cause mortality. On the other hand, alcohol is associated with an increased risk of cancer, neurological diseases, or injuries, among others. For years, efforts have been made to answer the question regarding the safe amount of alcohol intake, but controversies remain. Observational studies advocate moderate alcohol consumption following a Mediterranean pattern (red wine with meals avoiding binge drinking) as the best option for current drinkers. However, agencies such as the IARC recommend abstention from alcohol as it is a potent carcinogen. In this context, more randomized trial with larger sample size and hard clinical endpoints should be conducted to clarify the available evidence and provide clinicians with support for their clinical practice.

Keywords: alcohol; Mediterranean alcohol drinking pattern; Mediterranean diet; clinical trial; binge drinking; mendelian randomization; moderate consumption; abstinence

1. Introduction

Alcohol consumption represents an important global health problem and a priority for public health. The Sustainable Development Goals explicitly target the goal to strengthen the prevention and treatment of substance abuse including narcotic drug abuse and harmful use of alcohol [1]. Harmful alcohol use is ranked as the seventh global leading risk factor for death and disability [2]. Annually, three million deaths are attributed to alcohol, together with wider social harms that also extend beyond the drinker including intimate-partner violence (with a heavy burden on women), exacerbation of poverty, traffic injuries, and other effects [3].

Alcohol-related health problems are particularly severe in Europe. Europeans are the heaviest drinkers in the world, with an average intake of pure alcohol >25 g/d among adults, and a prevalence of current drinkers (in the last 12 months) of 72% (61.4% among women and 83.3% among men) \([4,5]\). The prevalence of heavy episodic drinking (≥60 g on ≥1 occasion during the past 30 days) was 30.4% in Europe. An estimate of 291,100 deaths in 2016 were attributed to alcohol consumption in Europe (5.5% of European deaths, 12% of premature mortality in men, and 2% in women) \([5]\). Alcohol represents the third leading factor for death and disability in Europe, responsible for €125 billion in costs per year \([6]\).

The burden of disease associated with alcohol consumption is usually assumed to result from an imbalance between beneficial and harmful effects. Nonrandomized epidemiologic studies have attributed some benefits to moderate alcohol consumption on ischemic heart disease, diabetes, or ischemic stroke, whereas they found detrimental effects on...
injury, suicide, several types of cancer, liver disease, mental disorders, and communicable diseases [2]. Considering the net balance, simple and generalized messages have been issued such as the safe level of alcohol intake should be zero [3,7–11] and “no level of alcohol consumption improves health” [7].

Absolute average alcohol intake does not seem to fully explain the shape of the dose–response relationship observed between alcohol intake and cardiovascular disease (CVD). Some aspects of the drinking pattern might act as effect modifiers including heavy episodic intake (binge drinking), beverage preference, consumption with or without meals, and distribution throughout the week [12–21]. Large cohorts concluded that ‘healthy’ patterns of moderate drinking reduce CVD [12,13,22–30], diabetes [31], and even all-cause mortality [32–38], particularly in subjects ≥50 years [26,29,39,40]. However, these cohorts included highly selected middle-to-high class subjects, highly educated subjects, or only health professionals. They also reported J-shaped associations for all-cause mortality. These effects might be dependent on the distribution of causes of death in the selected samples and on the distribution of levels of alcohol consumption in cohort participants, with few of them drinking high amounts or indulging in binge drinking [11]. This fact may compromise the strength of their potential causal inferences and generalizability [41–46].

In addition, studies using genetic instrumental variables or Mendelian randomization (MR) analyses have challenged that moderate alcohol consumption may reduce CVD or total mortality and support complete abstention as the healthiest option [47–50]. These analyses avoid the problems of self-selection for the drinking pattern, thus reducing confounding. They also provide a proxy of lifetime consumption and eliminate reverse causation. There are also limitations in MR analyses because, while MR analyses may contribute to identifying causal pathways, they cannot quantify the dose–response relationship between levels of alcohol consumption and mortality [51]. Several limitations specific to the genetic underpinnings of Mendelian randomization analyses do not allow them to be fully equiparated to randomized trials [51–53]. Some assumptions of the MR analyses have been challenged when analogies for achieving causal inferences have been made between the effect of the genetic variant in a MR study and the intention-to-treat effect in a randomized controlled trial (RCT).

There are four weaknesses in such an analogy, as reported elsewhere in further detail [53]. First, the compared groups with different genetic variants in MR may not be balanced, as they are in large RCTs, because of linkage disequilibrium, population stratification, or other reasons. Second, the genetic variant is not always causal, but it might only be a misclassified version of an assigned treatment strategy and the important assumption of a strong homogeneity effect within each group required for the use of instrumental variables is usually not met in MR studies because it would be biologically implausible. Third, the definition of treatment “adherence” (that permits one to differentiate between intention-to-treat and per-protocol analyses) is unclear in MR and cannot be properly defined because the treatment strategies are not explicitly described. Fourth, and very importantly, “time zero” of follow-up (i.e., the inception instant in a trial) is usually not well defined in a MR analyses. In a RCT, “time zero” corresponds to the coincidence of four facts: the moment when the eligibility criteria are met, random allocation, the onset of the treatment strategy, and the starting time for counting the events of interest (outcomes). This does not occur in MR studies where a lag of several decades exists between the time of pseudo-randomization (“treatment”), the time of eligibility, and the onset of outcome recordings. These timing mismatches do not sustain a perfect analogy between a MR analyses and a RCT for causal inference. Thus, MR studies, despite contributing to identifying causal pathways, cannot replace large and well conducted RCTs [52,53].

Modeling studies such as the Global Burden of Disease (GDB) [2,4–6,54] are also currently invoked to support that total abstinence is the healthiest alcohol dose [3,7,8]. Despite their utmost importance, these studies are in part based on some unfounded postulates [51]. They assume that true causal measures of effect are known for all relevant diseases and in all continents and countries as well as in the homeless, the less well-off strata, and other
sectors of the population. They also assume that all relevant effect modifiers have been identified (to ensure extrapolation of previous estimates obtained in highly selected cohorts to external populations) and that accurate prevalence estimates are available for all countries. However, this is not the case [41,51,54–56]. These models are likely to be highly sensitive to the selection and precision of their inputs, which are not always explicitly disclosed. For example, tuberculosis importantly contributed to the estimated disease burden attributed to alcohol [2], but the GBD study included tuberculosis and not Hodgkin’s disease or other hematologic malignancies that previously showed inverse associations with alcohol [54,57]. They also ignored the effect of the drinking pattern (problematic drinking is considerably more important for tuberculosis than moderate alcohol intake) [58,59]. Additionally, an increased risk of colorectal cancer is only supported for >3 drinks/d [60], however, a purely linear dose–response shape was assumed by the GBD.

Several mechanistic studies have attempted to explain the pathways that may link alcohol intake to the pathogenesis of diseases. Both cell damage and protective mechanisms have been found depending on the dose of ethanol. High concentrations of alcohol trigger oxidative and cardiotoxic mechanisms in cells causing cardiomyopathy, arrhythmias, and heart failure [61,62]. Underlying mechanisms that associate alcohol consumption with the development of diabetes mellitus in mice have also been found [63]. On the other hand, low and even moderate concentrations of alcohol caused anti-fibrillatory effects in atria [61] as well as increased HDL cholesterol levels and improved heart energy metabolism profile [64]. Resveratrol has also been proposed as an anti-fibrillatory agent through the modulation of ROS and oxidative stress [65]. Moreover, the mechanisms involved in the association between alcohol and cancer have also been extensively studied, especially for breast cancer, where they highlighted the harmful effects of ethanol on breast cancer cells such as growth promotion and angiogenesis [66,67]. They also found that cells repeatedly treated with alcohol increased their ability to migrate and metastasize other tissues [67–70]. Despite the limitations presented by the in vitro and in vivo studies, they suggest possible mechanisms underlying the association between alcohol intake and the risk of chronic disease.

Alcohol was classified as a group 1 carcinogen 30 years ago, and it imposes a severe toll on cancer, being responsible for 4.1% of all new cases of cancers in 2020 [6]. Alcohol is causally linked to cancers of the oral cavity, pharynx, larynx, liver, esophagus (squamous cell carcinoma), breast, and colo-rectum [6,59,60,71]. Even moderate levels of consumption (about 1–2 drinks/d) have been found associated with higher risks including cancer of the breast [71]. Nevertheless, some important cohorts have reported inverse associations of moderate alcohol intake with total cancer. The European Prospective Investigation into Cancer and Nutrition (EPIC) found the lowest cancer risks for alcohol intake between 6 and 25 g/d. Even for ‘alcohol-related’ cancers, the lowest risk was found for 12–25 g/d [72]. Two large American cohorts reported the lowest risk of cancer death for participants with consumptions of 1–5 g/d, not for abstainers [37,73].

The drinking pattern may act as an effect modifier even for the relationship between alcohol intake and liver cirrhosis. In fact, a recent analysis found a 31% relative reduction in the risk of cirrhosis among drinkers with meals compared to drinkers outside meals, adjusting for the quantity consumed [74–76].

Specifically, wine consumption, particularly in Mediterranean countries, has been postulated as a key feature of the Mediterranean diet with strong cardio-protective properties [77,78] due to the abundance of polyphenols in red wine with postulated antioxidant or anti-inflammatory effects [79–82]. Our group also found an interaction between alcohol intake and the overall drinking pattern on mortality [14,16,19], concluding that a traditional Mediterranean alcohol drinking pattern (MADP) (i.e., a moderate consumption of red wine during meals, spread out throughout the week, and avoidance of binge-drinking) was associated with lower mortality compared to abstinence or the departure from this MADP within constant levels of alcohol intake. A modification of the effect of the amount of alcohol intake on total mortality by the drinking patterns has been subsequently confirmed by recent large prospective studies conducted in the UK Biobank [75,76].
2. Methodological Problems in Nonrandomized Studies

The “sick quitter” effect and the “healthy user” effect are well-known methodological concerns of observational (i.e., nonrandomized) studies on alcohol. The first effect is explained because the group of non-drinkers may include former drinkers who quit due to illness, and the second one because healthier subjects are more likely to self-select themselves to drink moderately and more responsibly; this may confound the association between moderate alcohol intake and clinical outcomes and might provide a likely non-causal explanation on why, in some nonrandomized studies, abstainers showed a higher risk of chronic disease or all-cause mortality than moderate consumers of alcohol [83]. In addition, residual confounding by socioeconomic status, social integration, diet, lifestyles, health consciousness, and self-control cannot be ruled out in nonrandomized studies. In fact, in some meta-analyses, careful adjustment for potential confounders and other potential non-causal factors attenuated the reduction in mortality observed in moderate consumers [83–85]. A different caveat is that self-reported alcohol intake may lead to misclassification (underestimation of the true amount consumed in heavy drinkers) due to social desirability or unacceptability biases. Heavy drinkers may tend to underreport their true levels of alcohol consumption by up to 40% to 65% [86–89]. Systematic underreporting of alcohol use by heavy drinkers could result in overestimating the risks of adverse health outcomes associated with self-reported low-to-moderate amounts of alcohol, finding a non-true linear dose-dependent relationship with these adverse health outcomes, given that some heavy drinkers might be misclassified as only moderate drinkers due to their underreporting [87,89].

These speculations on nonrandomized studies are difficult to test or, in some cases, they have even been contradicted by empirical findings [40,79–82]. In fact, a large study reported that patients with certain medical conditions actually maintained higher alcohol intake than healthy subjects, thus contradicting the “healthy user” effect [90]. However, other data do support the “sick-quitter” and “healthy user” biases [91].

3. Diverging Recommendations

In this complex situation, a controversy currently exists regarding which is the best and most practical and realistic advice for drinkers aged 50–70 years old (Figure 1). Two completely opposite points of view are defended. On one hand, one point of view holds that complete abstention is the healthiest option for them, affirming that “there is no safe level of alcohol intake” for anybody and implying a strong need to reduce average alcohol consumption in all sectors of the population regardless of their initial consumption levels, their age, and their baseline risk. On the other hand, a harm reduction strategy for these adults leading to recommending “moderate” drinking (≤7 drinks/week in females and ≤14 in males) and avoidance of binge drinking is supported by wide sectors of the public health community including the U.S. Dietary Guidelines for Americans (DGA) 2015–2020, which recommended ≤2 drinks/d for males and ≤1 for females in 2015. The scientific report for the U.S. DGA 2020–2025 recommended moderation with ≤1 drink/d for both males and females, without substantial new evidence. Interestingly, in large U.S. cohorts, intakes of 5–15 g/d for women and 5–30 g/d for men represented one of the five elements of a lifestyle score robustly associated with longer life expectancy [37].

Therefore, both contradictory advices are apparently supported by nonrandomized cohorts, modeling studies, and meta-analyses [10,20,26,33,39–44,46–48,55,80,84,85,92]. This paradoxical situation is usually addressed only with plausible assumptions and speculations, but not with the needed firm evidence. Clinicians need evidence-based answers to clarify this controversy. Before opting for any of the two alternatives, the most sensible approach to overcome these controversies and the inherent limitations of measurement errors, selection biases, reverse causation, residual confounding, and misclassification would be to conduct a large RCT of alcohol with hard clinical endpoints among subjects older than 50 years. This task would represent a groundbreaking investigation with high risks and high gains, going beyond the current state-of-the-art. It would require interdisciplinary
work and could contribute enormously to the advancement of science by gaining sound evidence-based responses to the relevant and long-pending issue of what is the ideal option for alcohol intake among adults 50–70 years.

**ALCOHOL CONSUMPTION RECOMMENDATIONS**

| <50 years | ≥50 years |
|-----------|-----------|
| **ABSTENTION** |
| **CONTROVERSY** |
| Nonrandomized cohorts, modeling studies, meta-analyses |
| **CLARIFY** |
| Evidence-based answers |
| **Complete abstention** |
| No safe level of alcohol intake (IARC, 2004) |
| **“Moderate” drinking** |
| 9 ≤7 drinks/week |
| 15 ≤14 drinks/week |
| + Avoidance binge drinking (US Dietary Guidelines for Americans) |

Figure 1. Diverging recommendations on alcohol consumption.

This large and groundbreaking RCT is long overdue and has largely been warranted for decades. Given the potential biases inherent to nonrandomized studies [93–95], they may not be valid when the expected effects are likely to be actually null or only moderate, with relative risks less than two-fold [95]. This is most probably the case for the overall effects of light to moderate alcohol intake. As recently suggested by Collins et al., “large observational studies may yield misleading associations of a treatment with health outcomes that are statistically significant but non-causal, or that are mistakenly null when the treatment really does have clinically important effects. Instead, randomized, controlled trials of adequate size are generally required to ensure that any moderate benefits or moderate harms of a treatment are assessed reliably enough to guide patient care appropriately” [95].

In the era of evidence based-medicine and given the abundance of alcohol intake worldwide, it is surprising that no large RCT has ever been conducted to appropriately test the effects of alcohol. A previous attempt, the MACH15 trial, although nicely-designed and thoroughly planned, was terminated by the NIH and the funding withdrawn because of some suspicion on issues related to potential conflicts of interest with the alcohol industry. These issues were not clear. However, this unprecedented study was started and demonstrated the feasibility and timeliness of a trial on alcohol intake [96,97]. Unless a large RCT is conducted, discussions on alcohol issues upon mere assumptions and speculations on nonrandomized studies seem useless. A clear and definitive answer based on first-level evidence is of utmost need. A RCT should assess the effects of moderation versus abstention/reduction of alcohol intake on a holistic and comprehensive composite outcome including cardiovascular disease, cancer, other chronic diseases, injuries, major infectious diseases, and all-cause mortality, as previously claimed [55,56]. Although it may appear heterogeneous such a composite end-point is needed because alcohol is related to many (>200) individual diseases [4,9,41]. The balance between potential benefits and harms needs to be adequately considered if a large RCT is going to be started. Unless a large RCT is completed, starting from an agnostic perspective and free of competing interests, the needed first-level scientific evidence will continue elusive, and futile debate will continue for decades to come.
Funding agencies in the 21st century might risk leaving future generations without the needed knowledge and insights into the health effects of one of the most widely used substances by humanity for millennia, with Europeans currently as the highest consumers. The answer to this question also includes important economic and business consequences. Potential conflicts of interest highlight the need to publicly fund this RCT. Public funding and avoidance of any funding provided by the alcohol industry is key for an a priori completely agnostic approach, with no preferred expectations on any of the two compared alternatives, namely, abstention versus moderation.

4. Existing Randomized Controlled Trials in the Field of Alcohol Intervention

A number of short-term randomized feeding studies, conducted in small numbers of participants, have tested the effects of alcohol on several intermediate mechanisms. They predominantly examined the effects on lipids, inflammation, and glycemia [98], but not on hard clinical endpoints and cannot replace a formal large RCT. Alcohol intake raised the levels of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A1. Additionally, alcohol intake increased adiponectin, an adipokine that increases insulin sensitivity and is inversely associated with diabetes risk [98], reduced fasting levels of insulin and glycosylated hemoglobin [99], circulating levels of fibrinogen and prolonged bleeding time, thus affecting platelet function [100]. Other mechanistic findings are related to the effects of alcohol in increasing sex steroid hormones, particularly estrone [101] and dehydroepiandrosterone sulfate [102]. Alcohol exposure (three to four months in women) found important hormonal effects [102,103]. In the EPIC cohort, a formal mediation analysis reported that an alcohol-related hormonal signature (negatively associated with sex-hormone binding globulin and positively with estradiol and testosterone) was associated with increased breast cancer risk [104].

The longest trial to date of alcohol was the CArdiovaSCulAr Diabetes and Ethanol (CASCADE) trial, which lasted two years and included 224 participants with well-controlled type 2 diabetes [105]. All participants were initially alcohol abstainers, and they were randomly assigned 1:1:1 to consume, with dinner, 150 mL of mineral water, white wine, or red wine. Subjects randomized to initiate red wine increased their HDL-C and Apo A1 and reduced their number of components of the metabolic syndrome as compared to the mineral water group. No differences were found in other outcomes (glycemic control, blood pressure, adiposity, liver function, or quality of life). In Italy, a RCT with 131 patients with myocardial infarction and diabetes (Mediterranean-type diet with or without the addition of four daily ounces of red wine in a 1:1 ratio) reported higher levels of HDL for red wine, lower levels of oxidation markers, reductions in several inflammatory biomarkers, lower fasting insulin levels, and improved left ventricular function after one year [106]. Other small RCTs also tested the intermediate effects of alcohol including counseling to reduce intake [107–119].

Recently, a 6-month RCT in Australia with 140 drinkers (consuming approximately 120 g/week of pure alcohol at baseline) concluded that abstinence from alcohol reduced atrial fibrillation (AF) recurrences among drinkers with previous AF, who were in sinus rhythm at baseline [120]. The steering committee revised the protocol and shortened the follow-up to six months, instead of one year, because they did not find enough participants willing to abstain from alcohol for 12 months. This was the first RCT of alcohol with a clinical endpoint, and patients in the ‘abstinence’ group reduced their alcohol intake from 16.8 ± 7.7 to 2.1 ± 3.7 drinks/week (an 87.5% reduction), with complete abstinence achieved by 61% of participants in the abstinence group. Surprisingly, apart from these 140 drinkers to date, there is no other RCT in a free-living population evaluating the risk of any other major clinical outcome for two alternative advices on alcohol.
5. Mediterranean Alcohol Drinking Pattern, Wine in Moderation, and Reduced All-Cause Mortality

Previously, we operationally assessed the Mediterranean alcohol drinking pattern (MADP), defined as a moderate consumption of red wine during meals throughout the full week and avoidance of binge-drinking [14]. This MADP was inversely associated with all-cause mortality compared to alcohol abstinence. This is consistent with the so-called “French paradox”, a term coined three decades ago to try to explain the low rates of heart disease in the French population, together with a diet rich in saturated fats [121–124]. This paradox was attributed to usual wine consumption with meals [78–81,121–130]. The Greek EPIC cohort reported that none of the other nine items used to define the Mediterranean diet exerted such a strong benefit as moderate alcohol intake did on all-cause mortality. In that cohort, alcohol intake mainly came from wine consumed during meals [131]. These findings support the basis to defend the modifying effect of wine preference (as part of the drinking pattern) on the effect of total alcohol intake on all-cause mortality. Given the addictive nature of alcohol, and the inherent practical difficulties to achieve and maintain abstinence (or to get substantial reductions) in drinkers, a harm-reduction approach (namely, the MADP) can be appropriate for drinkers insofar as it is supported by scientific evidence.

6. Mediterranean Diet and Mediterranean-Alcohol Drinking Pattern, A Complex Relationship

Moderate alcohol consumption is one of the main components of the Mediterranean diet, which greatly contributes to the reduction in total mortality risk [131,132]. Many studies have focused on the determination of a safe level of alcohol intake, with mixed results from abstinence to moderate consumption [10,20,26,40–44,55,84,85]. However, rather than looking at each individual component, more attention should be paid to the overall pattern of consumption [78,133]. A large number of prospective studies reported a greater benefit from adherence to a Mediterranean dietary pattern than from the intake of a particular nutrient [133–136]. Therefore, an a priori Mediterranean pattern of alcohol consumption was proposed with positive results on mortality in Mediterranean cohorts [14,16,17,19,21,131,137]. These results suggest the existence of multiple coexisting and interrelated mechanisms. Antioxidant components of the diet and wine may reduce the carcinogenic effect of ethanol [138]. However, the evidence is limited and suggests a lower risk of all-cause mortality with high adherence to the Mediterranean dietary pattern together with MADP [19]. This complex relationship between diet and alcohol requires new lines of research to give more precise recommendations. In the absence of a RCT providing a higher level of evidence on alcohol consumption patterns, abstainers should not be recommended to start drinking, but those who do drink should be encouraged to follow the MADP in combination with the Mediterranean dietary pattern [19]. Once again, there is a clear need for an experimental trial to clarify the relationship between diet and alcohol to answer the question of a safe level of consumption.

7. Alcohol Consumption and Chronic Diseases

Alcohol consumption is associated with a higher risk of acute diseases (infections, injuries, traffic accidents, violence, fetal alcohol disorders, among others) and variable effects on chronic diseases (diabetes mellitus, digestive diseases, cancers, CVD). The harmful effects of alcohol are largely influenced by the total amount of ethanol ingested, the drinking pattern, and the specific type of alcoholic beverage consumed [12–18,20,21]. This is even more important when it comes to chronic alcohol consumption (Table 1). Several studies have associated repeated exposures to large amounts of ethanol in the blood with increased oxidative stress. This effect is likely to occur because during alcohol metabolism, reactive oxygen species (ROS) and nitrogen species (RNS) are produced, which cause oxidative stress, cell damage, inflammation, and DNA oxidation, leading to mutations. It also has the potential to decrease antioxidant activity and can lead to chronic diseases such as diabetes, organ inflammation, cardiovascular problems, or cancer [139–141].
Table 1. Alcohol consumption and chronic diseases.

| Protective Effects | Negative Effects |
|--------------------|------------------|
| Alcohol and CVD    |                  |
| Drinking pattern: low-moderate alcohol (♀≤7 drinks/week, ♂≤14 drinks/week) + with meals + avoid binge drinking | Chronic alcohol consumption, heavy drinking |
| Effects on blood pressure, atrial fibrillation, or strokes | High blood pressure, cardiomyopathy, coronary heart disease |
| Articles: [12,13,16,17,21–30,39,40,141] | Articles: [47–50,142–144] |

Alcohol and Diabetes Mellitus

| Low-moderate alcohol consumption | Chronic alcohol consumption, heavy drinking |
|---------------------------------|------------------------------------------|
| Reduced insulin resistance, HbA1c levels and CVD risk | Disruption in glucose homeostasis, higher insulin resistance, less adherence to diabetes treatment |
| Articles: [31,99,145] | Articles: [99,146,147] |

Alcohol and Digestive diseases

| Low-moderate consumption | Chronic alcohol consumption, heavy drinking |
|--------------------------|------------------------------------------|
| - | Hepatitis, chronic liver disease, cirrhosis, pancreatitis, gastritis |
| Articles: [148] | Articles: [2,4,149–155] |

Alcohol and Cancer

| Low (1–5 g/day), moderate (12–25 g/day) | All alcohol consumption, especially heavy and chronic patterns |
|----------------------------------------|-------------------------------------------------------------|
| Lowest risk of cancer (even alcohol related cancers) | Higher risk of breast, oropharynx, larynx, larynx, esophagus, liver, colon and rectum cancers |
| Articles: [37,73,74] | Articles: [2,4,6,59,60,71,72] |

7.1. Alcohol and CVD

Several nonrandomized studies have defended a J-shaped curve for the association between alcohol consumption and cardiovascular disease, with protective effects attributed to moderate consumption [12,13,16,17,22–30]. They emphasized the modifying effect of a moderate or healthier drinking pattern, particularly in subjects over 50 years of age [12–21,26,29,39,40], on potential alcohol beneficial effects on blood pressure, atrial fibrillation, or stroke [13,16,17,156]. One explanation for these potential benefits may lie in the antioxidant properties of wine, although there is still a large research gap to be filled [80–83]. On the other hand, some studies have argued for a linear association of alcohol with CVD or mortality [142–144] and attributed methodological problems and biases to the effects of moderate consumption and advocated zero alcohol [47–50].

7.2. Alcohol and Diabetes

Low-moderate alcohol consumption has been associated with reduced insulin resistance and HbA1c levels in non-diabetic patients and lower cardiovascular risk in diabetics [31,99,145]. However, there are studies that have challenged this claim as their findings also showed that diabetic patients who consumed alcohol adhered less to their treatment [146,147]. However, it is true that they agreed that chronic heavy drinking causes a disruption in glucose homeostasis, increases insulin resistance, and thus the risk of diabetes [99,146].

7.3. Alcohol and Digestive Diseases

The harmful effect of alcohol on the liver is well-known, leading to diseases such as hepatitis, chronic liver disease, and cirrhosis. Ethanol is metabolized in the liver, generating
oxidative compounds and the accumulation of fatty acids. Therefore, hepatitis C or alcoholic fatty liver disease are the result of chronic high alcohol consumption [2,4,149–153]. Furthermore, although the liver is the main organ affected, high alcohol consumption can lead to pancreatitis [149,154,155] or gastritis [153]. However, it is important to note that moderate patterns do not seem to be as associated with these diseases as high consumption [148].

7.4. Alcohol and Cancer

Cancer, like cardiovascular disease, is one of the leading causes of death in the world. Due to the oxidative compounds caused by alcohol metabolism, cells are more prone to mutations and therefore a direct link to cancer is assumed. Most organizations advocate zero alcohol consumption to prevent breast, oropharynx, larynx, larynx, esophagus, liver, colon, and rectum cancers [2,4,6,59,60,71,72]. However, similarly to previous diseases, cohort studies have found that low or moderate alcohol consumption is associated with a lower risk of cancer than the abstainer group [37,73,74].

8. Conclusions

Despite the possible limitations in the available evidence summarized in this review, the controversy regarding the potential effects of light to moderate alcohol consumption in subjects older than 45–50 years remains open. Clinicians need a sound, evidence-based, answer to this question to provide recommendations to their patients. Unless a long-term randomized clinical trial with hard clinical events as the end-point is conducted, this controversy will remain, and regardless of how large the cohort studies or meta-analyses of the nonrandomized study may be, the definitive answer will remain elusive.

Author Contributions: All three authors substantially contributed to the conceptualization, investigation, data curation, and writing. The first original draft was prepared by M.A.M.-G.; Writing—review and editing, M.B.-L. and A.G.; Supervision, M.A.M.-G. and A.G.; Project administration, M.A.M.-G. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: This is a review article with no new collection of data or intervention on human subjects, and consequently, there was no need to receive approval by any IRB.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. United Nations. Sustainable Development Goals. Goal 3 Targets. Available online: https://www.un.org/sustainabledevelopment/health/ (accessed on 30 March 2022).
2. GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2018, 392, 1015–1035. [CrossRef]
3. Casswell, S. Will alcohol harm get the global response it deserves? Lancet 2019, 394, 1396–1397. [CrossRef]
4. WHO. Global Status Report on Alcohol and Health 2018; World Health Organization: Geneva, Switzerland, 2018.
5. WHO Regional Office for Europe. Status Report on Alcohol Consumption, Harm and Policy Responses in 30 European Countries 2019; WHO Regional Office for Europe: Copenhagen, Denmark, 2019.
6. Rumgay, H.; Shield, K.; Charvat, H.; Ferrari, P.; Sormpiaisarn, B.; Obot, P.I.; Islami, F.; Lemmens, P.V.E.P.P.; Rehm, P.J.; Soerjomataram, I. Global burden of cancer in 2020 attributable to alcohol consumption: A population-based study. Lancet Oncol. 2021, 22, 1071–1080. [CrossRef]
7. Burton, R.; Sheron, N. No level of alcohol consumption improves health. Lancet 2018, 392, 987–988. [CrossRef]
8. Goiana-Da-Silva, F.; Cruz-E-Silva, D.; Lindeman, M.; Hellman, M.; Angus, C.; Karlsson, T.; Renström, M.; Ferreira-Borges, C. Implementing the European Action Plan on Alcohol. Lancet Public Health 2019, 4, e493. [CrossRef]
9. Rehm, J.; Bалиunas, D.; Borges, G.L.G.; Graham, K.; Irving, H.; Kehoe, T.; Parry, C.D.; Patra, J.; Popova, S.; Poznyak, V.; et al. The relation between different dimensions of alcohol consumption and burden of disease: An overview. Addiction 2010, 105, 817–843. [CrossRef]
10. Stockwell, T.; Naimi, T. Study raises new doubts regarding the hypothesized health benefits of ‘moderate’ alcohol use. *Evid. Based Med.* 2016, 21, 156. [CrossRef]

11. Naimi, T.S. Comment on Rehm: Alcohol, cohort studies and all-cause mortality: Where to from here? *Drug Alcohol Rev.* 2019, 38, 9–10. [CrossRef]

12. Mukamal, K.J.; Conigrave, K.M.; Mittleman, M.A.; Camargo, C.A., Jr.; Stamper, M.J.; Willett, W.C.; Rimm, E.B. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. *N. Engl. J. Med.* 2003, 348, 109–118. [CrossRef]

13. Ruidavets, J.-B.; Ducimetière, P.; Evans, A.; Montaye, M.; Haas, B.; Bingham, A.; Yarnell, J.; Amouyel, P.; Arveiler, D.; Kee, F.; et al. Patterns of alcohol consumption and ischemic heart disease in culturally divergent countries: The Prospective Epidemiological Study of Myocardial Infarction (PRIME). *BMJ* 2010, 341, c6077. [CrossRef]

14. Gea, A.; Bes-Rastrollo, M.; Toledo, E.; García-Lopez, M.; Beunza, J.J.; Estruch, R.; Martínez-Gonzalez, M.A. Mediterranean alcoholic-drinking pattern and mortality in the SUN (Seguimiento Universidad de Navarra) Project: A prospective cohort study. *Br. J. Nutr.* 2014, 111, 1871–1880. [CrossRef] [PubMed]

15. Roerecke, M.; Rehm, J. Alcohol consumption, drinking patterns, and ischemic heart disease: A narrative review of meta-analyses and a systematic review and meta-analysis of the impact of heavy drinking occasions on risk for moderate drinkers. *BMJ Clin. Res. Ed.* 2014, 12, 182. [CrossRef] [PubMed]

16. Hernandez-Hernandez, A.; Gea, A.; Ruiz-Canela, M.; Toledo, E.; Beunza, J.J.; Bes-Rastrollo, M.; Martinez-Gonzalez, M.A. Mediterranean Alcohol-Drinking Pattern and the Incidence of Cardiovascular Disease and Cardiovascular Mortality: The SUN Project. *Nutrients* 2015, 7, 9116–9126. [CrossRef]

17. Bazal, P.; Gea, A.; Martínez-González, M.A.; Salas-Salvadó, J.; Asensio, E.M.; Muñoz-Bravo, C.; Fiol, M.; Muñoz, M.-A.; Lapeta, J.; Serra-Majem, L.L.; et al. Mediterranean alcohol-drinking pattern, low to moderate alcohol intake and risk of atrial fibrillation in the PREMIDMED study. *Nutr. Metab. Cardiovasc. Dis.* 2019, 29, 676–683. [CrossRef]

18. Rehm, J.; Hasan, O.S.M. Is burden of disease differentially linked to spirits? A systematic scoping review and implications for alcohol policy. *Alcohol* 2020, 82, 1–10. [CrossRef] [PubMed]

19. Morales, G.; Martínez-González, M.A.; Barberia-Latasa, M.; Bes-Rastrollo, M.; Gea, A. Mediterranean diet, alcohol-drinking pattern and their combined effect on all-cause mortality: The Seguimiento Universidad de Navarra (SUN) cohort. *Eur. J. Nutr.* 2020, 60, 1489–1498. [CrossRef] [PubMed]

20. Giacosa, A.; Barale, R.; Bavaresco, L.; Faliva, M.A.; Gerbi, V.; La Vecchia, C.; Negri, E.; Opizzi, A.; Perna, S.; Pezzotti, M.; et al. Mediterranean Way of Drinking and Longevity. *Crit. Rev. Food Sci. Nutr.* 2016, 56, 635–640. [CrossRef]

21. Boban, M.; Stockley, C.; Teissedre, P.-L.; Restani, P.; Fradera, U.; Stein-Hammer, C.; Ruf, J.-C. Drinking pattern of wine and effects on human health: Why should we drink moderately and with meals? *Food Funct.* 2016, 7, 2937–2942. [CrossRef]

22. Bell, S.; Daskalopoulou, M.; Rapsomaniki, E.; George, J.; Britton, A.; Bobak, M.; Casas, J.P.; Dale, C.E.; Denaxas, S.; Shah, A.D.; et al. Association between clinically recorded alcohol consumption and initial presentation of 12 cardiovascular diseases: Population based cohort study using linked health records. *BMJ* 2017, 356, j909. [CrossRef]

23. Ronksley, P.E.; Brien, S.E.; Turner, B.J.; Mukamal, K.J.; Ghali, W.A. Association of alcohol consumption with selected cardiovascular disease outcomes: A systematic review and meta-analysis. *BMJ* 2011, 342, d671. [CrossRef]

24. Corrao, G.; Bagnardi, V.; Zambon, A.; La Vecchia, C. A meta-analysis of alcohol consumption and the risk of 15 diseases. *Prev. Med.* 2004, 38, 613–619. [CrossRef] [PubMed]

25. Di Castelnuovo, A.; Costanzo, S.; Bagnardi, V.; Donati, M.B.; Iacoviello, L.; de Gaetano, G. Alcohol dosing and total mortality in men and women: An updated meta-analysis of 34 prospective studies. *Arch. Intern. Med.* 2006, 166, 2437–2445. [CrossRef]

26. Yoon, S.-J.; Jung, J.-G.; Lee, S.; Kim, J.-S.; Ahn, S.-K.; Shin, E.-S.; Jang, J.-E.; Lim, S.-H. The protective effect of alcohol consumption on the incidence of cardiovascular diseases: Is it real? A systematic review and meta-analysis of studies conducted in community settings. *BMJ Public Health* 2020, 20, 90. [CrossRef] [PubMed]

27. Britton, K.A.; Gaziano, J.M.; Sesso, H.D.; Djoussé, L. Relation of alcohol consumption and coronary heart disease in hypertensive male physicians (from the Physicians’ Health Study’ Health). *Am. J. Cardiol.* 2009, 104, 932–935. [CrossRef] [PubMed]

28. Mukamal, K.J.; Chiuze, S.E.; Rimm, E.B. Alcohol consumption and risk for coronary heart disease in men with healthy lifestyles. *Arch. Intern. Med.* 2006, 166, 2145–2150. [CrossRef]

29. Hvidtfeldt, U.A.; Tolstrup, J.S.; Jakobsen, M.U.; Heitmann, B.L.; Grønbæk, M.; O’Reilly, E.; Bälté, K.; Goldbourt, U.; Hallmans, G.; Knek, P.; et al. Alcohol intake and risk of coronary heart disease in younger, middle-aged, and older adults. *Circulation* 2010, 121, 1589–1597. [CrossRef] [PubMed]

30. Arriola, L.; Cambler, P.M.; Larrañaga, N.; Basterretxea, M.; Amiano, P.; Moreno-Iribas, C.; Carracedo, R.; Agudo, A.; Ardanaz, E.; Barricante, A.; et al. Alcohol intake and the risk of coronary heart disease in the Spanish EPIC cohort study. *Heart* 2010, 96, 124–130. [CrossRef]

31. Howard, A.A.; Arnsten, J.H.; Gourevitch, M.N. Effect of alcohol consumption on diabetes mellitus: A systematic review. *Ann. Intern. Med.* 2004, 140, 211. [CrossRef]

32. Holman, C.D.; English, D.R.; Milne, E.; Winter, M.G. Meta-analysis of alcohol and all-cause mortality: A validation of NHMRC recommendations. *BMJ* 1996, 313, 141–145. [CrossRef]

33. Gmel, G.; Gotzler, E.; Rehm, J. How stable is the risk curve between alcohol and all-cause mortality and what factors influence the shape? A precision-weighted hierarchical meta-analysis. *Eur. J. Epidemiol.* 2003, 18, 631–642. [CrossRef]
34. Doll, R.; Peto, R.; Boreham, J.; Sutherland, I. Mortality in relation to alcohol consumption: A prospective study among male British doctors. *Int. J. Epidemiol.* 2005, 34, 199–204. [CrossRef] [PubMed]

35. Bellavia, A.; Bottai, M.; Wolk, A.; Orsini, N. Alcohol consumption and mortality: A dose-response analysis in terms of time. *Ann. Epidemiol.* 2014, 24, 291–296. [CrossRef] [PubMed]

36. Mostofsky, E.; Mukamal, K.J.; Giovannucci, E.L.; Stampfer, M.J.; Rimm, E.B. Key findings on alcohol consumption and a variety of health outcomes from the Nurses’ Health Study. *Am. J. Public Health* 2016, 106, 1586–1591. [CrossRef]

37. Li, Y.; Pan, A.; Wang, D.D.; Liu, X.; Dhana, K.; Franco, O.H.; Kaptoge, S.; Di Angelantonio, E.; Stampfer, M.; Willett, W.C.; et al. Impact of Healthy Lifestyle Factors on Life Expectancies in the US Population. *Circulation* 2018, 138, 345–355. [CrossRef] [PubMed]

38. Keyes, K.M.; Calvo, E.; Ornstein, K.A.; Rutherford, C.; Fox, M.P.; Staudinger, U.M.; Fried, L.P. Alcohol Consumption in Later Life and Mortality in the United States: Results from 9 Waves of the Health and Retirement Study. *Alcohol Clin. Exp. Res.* 2019, 43, 1734–1746. [CrossRef]

39. Zhao, J.; Stockwell, T.; Roemer, A.; Naimi, T.; Chikritzhs, T. Alcohol Consumption and Mortality from Coronary Heart Disease: An Updated Meta-Analysis of Cohort Studies. *J. Stud. Alcohol Drugs* 2017, 78, 375–386. [CrossRef]

40. Martínez-González, M.A.; Barberia-Latas, M.; Pérez de Rojas, J.; Domínguez Rodriguez, L.J.; Gea, A. Alcohol and early mortality (before 65 years) in the ‘Seguimiento Universidad de Navarra’ (SUN) cohort: Does any level reduce mortality? *Br. J. Nutr.* 2021, 127, 1415–1425. [CrossRef]

41. Rehm, J. Why the relationship between level of alcohol-use and all-cause mortality cannot be addressed with meta-analyses of cohort studies. *Drug Alcohol Rev.* 2019, 38, 3–4. [CrossRef]

42. Stockwell, T. Greater precision at the price of greater uncertainty? A response to Rehm. *Drug Alcohol Rev.* 2019, 38, 5–6. [CrossRef]

43. Angus, C.; Holmes, J. The allure, and challenges, of complexity in epidemiological modelling of alcohol harm: Commentary on Rehm. *Drug Alcohol Rev.* 2019, 38, 11–12. [CrossRef]

44. Naimi, T.S.; Stockwell, T.; Zhao, J.; Xuan, Z.; Dangardt, F.; Saitz, R.; Liang, W.; Chikritzhs, T. Selection biases in observational studies affect associations between ‘moderate’ alcohol consumption and mortality. *Addiction* 2017, 112, 207–214. [CrossRef] [PubMed]

45. Fillmore, K.M.; Kerr, W.C.; Stockwell, T.; Chikritzhs, T.; Bostrom, A. Moderate alcohol use and reduced mortality risk: A systematic error in prospective studies. *Addict Res. Theory* 2006, 14, 101–132. [CrossRef]

46. Naimi, T.S.; Brown, D.W.; Brewer, R.D.; Giles, W.H.; Mensah, A.; Mokdad, A.H.; Hungerford, D.W.; Lando, J.; Naimi, S.; et al. Cardiovascular risk factors and confounders among nondrinking and moderate-drinking US. *Adults. Am. J. Prev. Med.* 2005, 28, 369–373. [CrossRef] [PubMed]

47. Holmes, M.V.; Dale, C.E.; Zuccolo, L.; Silverwood, R.J.; Guo, Y.; Ye, Z.; Prieto-Merino, D.; Dehghan, A.; Trompet, S.; Wong, A.; et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. *BMJ* 2014, 349, g4164. [CrossRef]

48. Millwood, I.Y.; Walters, R.G.; Mei, X.W.; Guo, Y.; Yang, L.; Bian, Z.; Bennett, D.A.; Chen, Y.; Dong, C.; Hu, R.; et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: A prospective study of 500,000 men and women in China. *Lancet* 2019, 393, 1831–1842. [CrossRef]

49. Chikritzhs, T.; Stockwell, T.; Naimi, T.; Andreasson, S.; Dangardt, F.; Liang, W. Has the leaning tower of presumed health benefits from “moderate” alcohol use finally collapsed? *Addiction* 2015, 110, 726–727. [CrossRef]

50. Yang, J.H.; Jeong, J.A.; Kweon, S.S.; Lee, Y.H.; Choi, S.W.; Ryu, S.Y.; Nam, H.S.; Park, K.S.; Kim, H.Y.; Shin, M.H. Causal Association Between Alcohol Consumption and Atrial Fibrillation: A Mendelian Randomization Study. *Korean Circ. J.* 2022, 52, 220–230. [CrossRef]

51. Rehm, J. Alcohol consumption and all-cause mortality: Further implications. *Drug Alcohol Rev.* 2019, 38, 13–15. [CrossRef]

52. Swanson, S.A.; Temeier, H.; Ikram, M.A.; Hernan, M.A. Nature as a Trialist? Deconstructing the Analogy Between Mendelian Randomization and Randomized Trials. *Epidemiol. 2017*, 28, 653–659. [CrossRef]

53. Mukamal, K.J.; Stampfer, M.J.; Rimm, E.B. Genetic instrumental variable analysis: Time to call mendelian randomization what it is. The example of alcohol and cardiovascular disease. *Eur. J. Epidemiol.* 2020, 35, 93–97. [CrossRef]

54. GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. *Lancet Psychiatry* 2018, 5, 987–1012. [CrossRef]

55. Mukamal, K.J. A safe level of alcohol consumption: The right answer demands the right question. *J. Intern. Med.* 2020, 288, 550–559. [CrossRef] [PubMed]

56. Mukamal, K.J.; Clowry, C.M.; Murray, M.M.; Hendriks, H.F.; Rimm, E.B.; Sink, K.M.; Adebamowo, C.A.; Dragstedt, L.O.; Lapinski, P.S.; Lazo, M.; et al. Moderate Alcohol Consumption and Chronic Disease: The Case for a Long-Term Trial. *Alcohol Clin. Exp. Res.* 2016, 40, 2283–2291. [CrossRef] [PubMed]

57. Psaltopoulou, T.; Sergentanis, T.N.; Ntanasis-Stathopoulos, I.; Tzanninis, I.G.; Tsilimigras, D.I.; Dimopoulos, M.A. Alcohol consumption and risk of hematological malignancies: A meta-analysis of prospective studies. *Int. J. Cancer* 2018, 143, 486–495. [CrossRef] [PubMed]

58. Imtiaz, S.; Shield, K.D.; Roerecke, M.; Samokhvalov, A.V.; Lonnroth, K.; Rehm, J. Alcohol consumption as a risk factor for tuberculosis: Meta-analyses and burden of disease. *Eur. Respir. J.* 2017, 50, 1700216. [CrossRef] [PubMed]
59. Shield, K.; Manthey, J.; Rylett, M.; Probst, C.; Wettlaufer, A.; Parry, C.D.H.; Rehm, J. National, regional, and global burdens of disease from 2000 to 2016 attributable to alcohol use: A comparative risk assessment study. *Lancet Public Health* 2020, 5, e51–e61. [CrossRef]

60. McNabb, S.; Harrison, T.A.; Albanes, D.; Berndt, S.I.; Brenner, H.; Caan, B.J.; Campbell, P.T.; Cao, Y.; Chang-Claude, J.; Chan, A.; et al. Meta-analysis of 16 studies of the association of alcohol with colorectal cancer. *Int. J. Cancer* 2020, 146, 861–873. [CrossRef]

61. Sutanto, H.; Cluitmans, M.J.M.; Dobrev, D.; Volders, P.G.A.; Bébarová, M.; Heijman, J. Acute effects of alcohol on cardiac electrophysiology and arrhythmogenesis: Insights from multiscale in silico analyses. *J. Mol. Cell Cardiol.* 2020, 146, 69–83. [CrossRef]

62. Liu, R.; Sun, F.; Armand, L.C.; Wu, R.; Xu, C. Chronic Ethanol Exposure Induces Deleterious Changes in Cardiomyocytes Derived from Human Induced Pluripotent Stem Cells. *Stem. Cell Rev. Rep.* 2021, 17, 2314–2331. [CrossRef]

63. Singh, S.; Chen, Y.; Matsumoto, A.; Orlicky, D.J.; Dong, H.; Thompson, D.C.; Vasiliou, V. ALDH1B1 links alcohol consumption and diabetes. *Biochem. Biophys. Res. Commun.* 2015, 463, 768–773. [CrossRef]

64. Fan, F.; Cao, Q.; Wang, C.; Ma, X.; Shen, C.; Liu, X.W.; Bu, L.P.; Zou, Y.Z.; Hu, K.; Sun, A.J.; et al. Impact of chronic low to moderate alcohol consumption on blood lipid and heart energy profile in acetaldehyde dehydrogenase 2-deficient mice. *Acta Pharmacol. Sin.* 2014, 35, 1015–1022. [CrossRef] [PubMed]

65. Sutanto, H.; Dobrev, D.; Heijman, J. Resveratrol: An effective pharmacological agent to prevent inflammation-induced atrial fibrillation? *Naunyn Schmiedebergs Arch. Pharmacol.* 2018, 391, 1163–1167. [CrossRef] [PubMed]

66. Wang, S.; Xu, M.; Li, F.; Wang, X.; Bower, K.A.; Frank, J.A.; Lu, Y.; Chen, G.; Zhang, Z.; Ke, Z.; et al. Ethanol promotes mammary tumor growth and angiogenesis: The involvement of chemoattractant factor MCP-1. *Breast Cancer Res. Treat.* 2012, 133, 1037–1048. [CrossRef] [PubMed]

67. Xu, M.; Ren, Z.; Wang, X.; Comer, A.; Frank, J.A.; Ke, Z.J.; Huang, Y.; Zhang, Z.; Shi, X.; Wang, S.; et al. ErbB2 and p38 MAPK mediate alcohol-induced increase in breast cancer stem cells and metastasis. *Mol. Cancer* 2016, 15, 52. [CrossRef]

68. Xu, M.; Wang, S.; Ren, Z.; Frank, J.A.; Yang, X.H.; Zhang, Z.; Ke, Z.J.; Shi, X.; Luo, J. Chronic ethanol exposure enhances the aggressiveness of breast cancer: The role of p38y. *Oncotarget* 2016, 7, 3489–3505. [CrossRef] [PubMed]

69. Zhao, M.; Howard, E.W.; Parris, A.B.; Guo, Z.; Zhao, Q.; Yang, X. Alcohol promotes migration and invasion of triple-negative breast cancer cells through activation of p38 MAPK and JNK. *Mol. Carcinog.* 2017, 56, 849–862. [CrossRef] [PubMed]

70. Müller, M.F.; Zhou, Y.; Adams, D.J.; Arends, M.J. Effects of long-term ethanol consumption and Aldh1b1 depletion on intestinal tumourigenesis in mice. *J. Pathol.* 2017, 241, 649–660. [CrossRef]

71. Klein, W.M.P.; Jacobsen, P.B.; Helzlsouer, K.J. Alcohol and cancer risk. Clinical and research implications. *JAMA* 2020, 323, 23–24. [CrossRef] [PubMed]

72. Bagnardi, V.; Rota, M.; Botteri, E.; Tramacere, I.; Islami, F.; Fedirko, V.; Scotti, L.; Ferrari, P.; Biessy, C.; Freisling, H.; et al. Alcohol consumption and site-specific cancer risk: A comprehensive dose-response meta-analysis. *Br. J. Cancer* 2016, 112, 580–593. [CrossRef] [PubMed]

73. McKenzie, F.; Biessy, C.; Ferrari, P.; Freisling, H.; Rinaldi, S.; Chajine, V.; Ahmed, S.; Overvad, K.; Dossus, L.; Lagiou, P.; et al. Healthy Lifestyle and Risk of Cancer in the European Prospective Investigation into Cancer and Nutrition Cohort Study. *Medicine* 2016, 95, e2850. [CrossRef]

74. Cao, Y.; Willett, W.C.; Stampfer, M.J.; Giovannucci, E.L. Light to moderate intake of alcohol, drinking patterns, and risk of cancer: Results from two prospective US cohort studies. *BMJ* 2015, 351, h4238. [CrossRef] [PubMed]

75. Simpson, R.F.; Hermon, C.; Liu, B.; Reeves, G.K.; Beral, V.; Floud, S. Million Women Study Collaborators. Alcohol drinking patterns and liver cirrhosis risk: Analysis of the prospective UK Million Women Study. *Lancet Public Health* 2019, 5, h4238. [CrossRef] [PubMed]

76. Ma, H.; Li, X.; Zhou, T.; Sun, D.; Shai, I.; Heianza, Y.; Rimm, E.B.; Manson, J.E.; Qi, L. Alcohol Consumption Levels as Compared With Drinking Habits in Predicting All-Cause Mortality and Cause-Specific Mortality in Current Drinkers. *Mayo. Clin. Proc.* 2021, 96, 1758–1769. [CrossRef] [PubMed]

77. Jani, B.D.; McQueenie, R.; Nicholl, B.L.; Field, R.; Hanlon, P.; Gallacher, K.I.; Mair, F.S.; Lewsey, J. Association between patterns of alcohol consumption (beverage type, frequency and consumption with food) and risk of adverse health outcomes: A prospective cohort study. *BMC Med.* 2021, 19, 8. [CrossRef] [PubMed]

78. Martinez-González, M.A.; Sánchez-Villegas, A. The emerging role of Mediterranean diets in cardiovascular epidemiology: Monounsaturated fats olive oil red wine or the whole pattern? *Eur. J. Epidemiol.* 2004, 19, 9–13. [CrossRef]

79. Martinez-González, M.A.; Gea, A.; Ruiz-Canela, M. The Mediterranean Diet and Cardiovascular Health. *Circ. Res.* 2019, 124, 779–798. [CrossRef]

80. Klat sky, A.L. Alcohol and cardiovascular mortality: Common sense and scientific truth. *J. Am. Coll. Cardiol.* 2010, 55, 1336–1338. [CrossRef]

81. Haseeb, S.; Alexander, B.; Baranchuk, A. Wine and Cardiovascular Health: A Comprehensive Review. *Circulation* 2017, 136, 1434–1448. [CrossRef]

82. Pavlidou, E.; Mantzorou, M.; Fasoulas, A.; Tryfonos, C.; Petridis, D.; Giaginis, C. Wine: An Aspiring Agent in Promoting Longevity and Preventing Chronic Diseases. *Diseases* 2018, 6, 73. [CrossRef]
83. Ditano-Vázquez, P.; Torres-Peña, J.D.; Galeano-Valle, F.; Pérez-Caballero, A.I.; Demelo-Rodriguez, P.; Lopez-Miranda, J.; Katsiki, N.; Delgado-Lista, J.; Alvarez-Sala-Walther, L.A. The Fluid Aspect of the Mediterranean Diet in the Prevention and Management of Cardiovascular Disease and Diabetes: The Role of Polyphenol Content in Moderate Consumption of Wine and Olive Oil. *Nutrients* 2019, 11, 2833. [CrossRef]

84. Shaper, A.G.; Wannamethee, G.; Walker, M. Alcohol and mortality in British men: Explaining the U-shaped curve. *Lancet* 1988, 2, 1267–1273. [CrossRef]

85. Fillmore, K.M.; Stockwell, T.; Chikritzhs, T.; Bostrom, A.; Kerr, W. Moderate alcohol use and reduced mortality risk: Systematic error in prospective studies and new hypotheses. *Ann. Epidemiol.* 2007, 17 (Suppl. S5), S16–S23. [CrossRef] [PubMed]

86. Stockwell, T.; Zhao, J.; Panwar, S.; Roemer, A.; Naimi, T.; Chikritzhs, T. Do “moderate” drinkers have reduced mortality risk? A systematic review and meta-analysis of alcohol consumption and all-cause mortality. *J. Stud. Alcohol Drugs* 2016, 77, 185–198. [CrossRef] [PubMed]

87. Stockwell, T.; Zhao, J.; Macdonald, S. Who under-reports their alcohol consumption in telephone surveys and by how much? An application of the “yesterday method” in a national Canadian substance use survey. *Addiction* 2014, 109, 1657–1666. [CrossRef] [PubMed]

88. Esser, M.B.; Sherk, A.; Subbaraman, M.S.; Martinez, P.; Karriker-Jaffe, K.J.; Sacks, J.J.; Naimi, T.S. Improving Estimates of Alcohol-Attributable Deaths in the United States: Impact of Adjusting for the Underreporting of Alcohol Consumption. *J. Stud. Alcohol Drugs* 2022, 83, 134–144. [CrossRef]

89. Vance, M.C.; Caverly, T.J.; Hayward, R.A. Underappreciated Bias Created by Measurement Error in Risk Factor Assessment—A Case Study of No Safe Level of Alcohol Consumption. *JAMA Intern. Med.* 2019, 180, 459–461. [CrossRef] [PubMed]

90. Sterling, S.A.; Palzes, V.A.; Lu, Y.; Kline-Simon, A.H.; Parhasarthathy, S.; Ross, T.; Elson, J.; Weisner, C.; Maxim, C.; Chi, F.W. Associations Between Medical Conditions and Alcohol Consumption Levels in an Adult Primary Care Population. *JAMA Netw. Open.* 2020, 3, e204687. [CrossRef]

91. Palzes, V.A.; Kline-Simon, A.H.; Satre, D.D.; Sterling, S.; Weisner, C.; Chi, F.W. Predictors of early and sustained cessation of heavy drinking over 5 years among adult primary care patients. *Addiction* 2022, 117, 82–95. [CrossRef]

92. Davey Smith, G.; Holmes, M.V.; Davies, N.M.; Ebrahim, S. Mendel’s laws, Mendelian randomization and causal inference in observational data: Substantive and nomenclatural issues. *Eur. J. Epidemiol.* 2020, 35, 99–111. [CrossRef]

93. Forbes, S.P.; Dahabreh, I.J. Benchmarking Observational Analyses Against Randomized Trials: A Review of Studies Assessing Propensity Score Methods. *J. Gen. Intern. Med.* 2020, 35, 1396–1404. [CrossRef]

94. Califf, R.M.; Hernandez, A.F.; Landray, M. Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments: Observational Cacophony, Randomized Harmony. *JAMA* 2020, 324, 625–626. [CrossRef] [PubMed]

95. Collins, R.; Bowman, L.; Landray, M.; Peto, R. The Magic of Randomization versus the Myth of Real-World Evidence. *N. Engl. J. Med.* 2020, 382, 674–678. [CrossRef] [PubMed]

96. Spiegelman, D.; Lovato, L.C.; Khudyakov, P.; Wilkens, T.L.; Adebamowo, C.A.; Adebamowo, S.N.; Appel, L.J.; Beulens, J.W.; Coughlin, J.W.; Dragsted, L.O.; et al. The Moderate Alcohol and Cardiovascular Health Trial (MACH15): Design and methods for a randomized trial of moderate alcohol consumption and cardiometabolic risk. *Eur. J. Prev. Cardiol.* 2020, 27, 1967–1982. [CrossRef] [PubMed]

97. Miller, L.M.; Anderson, C.A.; Isx, J.H. Editorial: From MACH15 to MACH0—A missed opportunity to understand the health effects of moderate alcohol intake. *Eur. J. Prev. Cardiol.* 2020, 28, e23–e24. [CrossRef] [PubMed]

98. Brien, S.E.; Ronsksley, P.E.; Turner, B.J.; Mukamal, K.J.; Ghali, W.A. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: A systematic review and meta-analysis of intervention studies. *BMJ* 2011, 342, d636. [CrossRef] [PubMed]

99. Schrieks, I.C.; Heil, A.L.; Hendriks, H.F.; Mukamal, K.J.; Beulens, J.W. The effect of alcohol consumption on insulin sensitivity and glycemic status: A systematic review and meta-analysis of intervention studies. *Diabetes Care* 2015, 38, 723–732. [CrossRef] [PubMed]

100. Deykin, D.; Janson, P.; McMahon, L. Ethanol potentiation of aspirin-induced prolongation of the bleeding time. *N. Engl. J. Med.* 1982, 306, 852–854. [CrossRef]

101. Mahabir, S.; Baer, D.J.; Johnson, L.L.; Dorgan, J.F.; Campbell, W.; Brown, E.; Hartman, T.J.; Clevidence, B.; Albanes, D.; Judd, J.T.; et al. The effects of moderate alcohol supplementation on estrone sulfate and DHEAS in postmenopausal women in a controlled feeding study. *Nutr. J.* 2004, 3, 11. [CrossRef]

102. Reichman, M.E.; Judd, J.T.; Longcope, C.; Schatzkin, A.; Albert, P.S.; Dorgan, J.F.; Clevidence, B.A.; Campbell, W.S.; et al. Moderate alcohol consumption and levels of antioxidant vitamins and isoprostanes in postmenopausal women. *Eur. J. Clin. Nutr.* 2005, 59, 161–168. [CrossRef]

103. Hartman, T.J.; Baer, D.J.; Graham, L.B.; Stone, W.L.; Gunter, E.W.; Parker, C.E.; Albert, P.S.; Dorgan, J.F.; Clevidence, B.A.; Campbell, W.S.; et al. Moderate alcohol consumption and levels of antioxidant vitamins and isoprostanes in postmenopausal women. *Eur. J. Clin. Nutr.* 2005, 59, 161–168. [CrossRef] [PubMed]

104. Assi, N.; Rinaldi, S.; Viallon, V.; Dashti, S.G.; Dossus, L.; Fourrier, A.; Cervenka, I.; Kvaskoff, M.; Turzanski-Fortner, R.; Bergmann, M.; et al. Mediation analysis of the alcohol-postmenopausal breast cancer relationship by sex hormones in the EPIC cohort. *Int. J. Cancer* 2020, 146, 759–768. [CrossRef] [PubMed]
105. Gepner, Y.; Golan, R.; Harman-Boehm, I.; Henkin, Y.; Schwarzfuchs, D.; Shelef, I.; Durst, R.; Kovsyan, J.; Bolotin, A.; Leitersdorf, E. Effects of initiating moderate alcohol intake on cardiometabolic risk in adults with type 2 diabetes: A 2-year randomized, controlled trial. *Ann. Intern. Med.* 2015, 163, 569–579. [CrossRef] [PubMed]

106. Marfella, R.; Cacciapuoti, F.; Siniscalchi, M.; Sasso, F.C.; Marchese, F.; Cinone, F.; Musacchio, E.; Marfella, M.A.; Ruggiero, L.; Chiorazzo, G.; et al. Effect of moderate red wine intake on cardiac prognosis after recent acute myocardial infarction of subjects with Type 2 diabetes mellitus. *Diabet. Med.* 2006, 23, 974–981. [CrossRef]

107. Rimm, E.B.; Williams, P.; Fosher, K.; Criqui, M.; Stampfer, M.J. Moderate alcohol intake and lower risk of coronary heart disease: Meta-analysis of effects on lipids and haemostatic factors. *BMJ* 1999, 319, 1523–1528. [CrossRef]

108. Puddrey, I.B.; Beilin, L.J.; Vandongen, R.; Rouse, I.L.; Rogers, P. Evidence for a direct effect of alcohol consumption on blood pressure in normotensive men. A randomized controlled trial. *Hypertension* 1985, 7, 707–713. [CrossRef] [PubMed]

109. Shai, I.; Wainstein, J.; Harman-Boehm, I.; Raz, I.; Fraser, D.; Rudich, A.; Stampfer, M.J. Glycemic effects of moderate alcohol intake among patients with type 2 diabetes: A multicenter, randomized, clinical intervention trial. *Diabetes Care* 2007, 30, 3011–3016. [CrossRef]

110. Sierksma, A.; van der Gaag, M.S.; Klut, C.; Hendriks, H.F. Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study. *Eur. J. Clin. Nutr.* 2002, 56, 1130–1136. [CrossRef] [PubMed]

111. Sierksma, A.; Sarkola, T.; Eriksson, C.J.; van der Gaag, M.S.; Grobbee, D.E. Hendriks, H.F. Effect of moderate alcohol consumption on plasma dehydroepiandrosterone sulfate, testosterone, and estradiol levels in middle-aged men and postmenopausal women: A diet-controlled intervention study. *Alcohol Clin. Exp. Res.* 2004, 28, 780–785. [CrossRef]

112. Huang, Y.; Li, Y.; Zheng, S.; Yang, X.; Wang, T.; Zeng, J. Moderate alcohol consumption and atherosclerosis: Meta-analysis of effects on lipids and inflammation. *Wien. Klin. Wochenschr.* 2017, 129, 833–843. [CrossRef]

113. Kaner, E.F.; Dickinson, H.O.; Beyer, F.R.; Campbell, F.; Schlesinger, C.; Heather, N.; Saunders, J.B.; Burmand, B.; Pienaar, E.D. Effectiveness of brief alcohol interventions in primary care populations. *Cochrane Database Syst. Rev.* 2018, 2, CD004148. [CrossRef]

114. Kaner, E.F.; Beyer, F.R.; Garnett, C.; Crane, D.; Brown, J.; Muihead, C.; Redmore, J.; O’Donnell, A.; Newham, J.J.; de Vocht, F. Personalised digital interventions for reducing hazardous and harmful alcohol consumption in community-dwelling populations. *Cochrane Database Syst. Rev.* 2017, 9, CD011479. [CrossRef] [PubMed]

115. Field, M.; Puddeh, J.A.; Goodwin, L.; Owens, L.; Reaves, D.; Holmes, J. Benefits of temporary alcohol restriction: A feasibility randomized trial. *Pilot Feasibility Stud.* 2020, 6, 9. [CrossRef] [PubMed]

116. Grekin, E.R.; Beatty, J.R.; McGoron, L.; Kugler, K.C.; McClure, J.B.; Pop, D.E.; Ondersma, S.J. Testing the efficacy of motivational strategies, empathic reflections, and life-like features in a computerized intervention for alcohol use: A factorial trial. *Psychol. Addict. Behav.* 2019, 33, 511–519. [CrossRef] [PubMed]

117. Dedert, E.A.; McDuffie, J.R.; Stein, R.; McNiel, J.M.; Kosinski, A.S.; Freirimuth, C.E.; Hemminger, A.; Williams, J.W., Jr. Electronic Interventions for Alcohol Misuse and Alcohol Use Disorders: A Systematic Review. *Ann. Intern. Med.* 2015, 163, 205–214. [CrossRef]

118. Jonas, D.E.; Garbutt, J.C.; Amick, H.R.; Brown, J.M.; Brownley, K.A.; Council, C.L.; Viera, A.J.; Wilkins, T.M.; Schwartz, C.J.; Richmond, E.M. Behavioral counseling after screening for alcohol misuse in primary care: A systematic review and meta-analysis for the U.S. Preventive Services Task Force. *Ann. Intern. Med.* 2012, 157, 645–654. [CrossRef]

119. O’Connor, E.A.; Perdue, L.A.; Senger, C.A.; Rushkin, M.; Patnode, C.D.; Bean, S.I.; Jonas, D.E. Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA* 2018, 320, 1910–1928. [CrossRef]

120. Voskoboinik, A.; Kalman, J.M.; De Silva, A.; Nicholls, T.; Costello, B.; Nanayakkara, S.; Prabhu, S.; Stub, D.; Azzopardi, S.; Vizi, D.; et al. Alcohol abstinence in drinkers with atrial fibrillation. *N. Engl. J. Med.* 2020, 382, 20–28. [CrossRef] [PubMed]

121. Renaud, S.; de Lorgeril, M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. *Lancet* 1992, 339, 1523–1526. [CrossRef]

122. Criqui, M.H.; Riget, B.L. Does diet or alcohol explain the French paradox? *Lancet* 1994, 344, 1719–1723. [CrossRef]

123. Lippi, G.; Franchini, M.; Favaro, E.J.; Targher, G. Moderate red wine consumption and cardiovascular disease risk: Beyond the “French paradox”. *Semin. Thromb. Hemost.* 2010, 36, 59–70. [CrossRef] [PubMed]

124. Fragopoulou, E.; Antonopoulou, S. The French paradox three decades later: Role of inflammation and thrombosis. *Clin. Chim. Acta* 2020, 510, 160–169. [CrossRef] [PubMed]

125. Grønbaek, M.; Becker, U.; Johansen, D.; Gottschau, A.; Schnohr, P.; Hein, H.O.; Jensen, G.; Sørensen, T.I. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. *Ann. Intern. Med.* 2000, 133, 411–419. [CrossRef] [PubMed]

126. De Gaetano, G.; Cerletti, C. Wine and cardiovascular disease. *Nutr. Metab. Cardiovasc. Dis.* 2001, 11 (Suppl. S4), 47–50. [PubMed]

127. Fernández-Jarne, E.; Martínez-Losa, E.; Serrano-Martínez, P.; Prado-Santamaría, M.; Brugarolas-Brufau, C.; Martínez-González, M.A. Type of alcoholic beverage and first acute myocardial infarction: A case-control study in a Mediterranean country. *Clin. Cardiol.* 2003, 26, 313–318. [CrossRef]

128. Harriss, L.R.; English, D.R.; Hopper, J.L.; Powles, J.; Simpson, J.A.; O’Dea, K.; Giles, G.G.; Tonkin, A.M. Alcohol consumption and cardiovascular mortality accounting for possible misclassification of intake: 11-year follow-up of the Melbourne Collaborative Cohort Study. *Addiction* 2007, 102, 1574–1585. [CrossRef] [PubMed]
129. Streppel, M.T.; Ocké, M.C.; Boshuizen, H.C.; Kok, F.J.; Kromhout, D. Long-term wine consumption is related to cardiovascular mortality and life expectancy independently of moderate alcohol intake: The Zutphen Study. *J. Epidemiol. Community Health* 2009, 63, 534–540. [CrossRef]

130. Arranz, S.; Chiva-Blanch, G.; Valderas-Martínez, P.; Medina-Remón, A.; Lamuela-Raventós, R.M.; Estruch, R. Wine, beer, alcohol and polyphenols on cardiovascular disease and cancer. *Nutrients* 2012, 4, 759–781. [CrossRef]

131. Trichopoulos, A.; Bamia, C.; Trichopoulos, D. Anatomy of health effects of Mediterranean diet: Greek EPIC prospective cohort study. *BMJ* 2009, 338, b2337. [CrossRef]

132. Willett, W.C.; Sacks, F.; Trichopoulos, D.; Drescher, G.; Ferro-Luzzi, A.; Helsing, E.; Trichopoulos, D. Mediterranean diet pyramid: A cultural model for healthy eating. *Am. J. Clin. Nutr.* 1995, 61 (Suppl. S6), 140S–146S. [CrossRef]

133. Hu, F.B. Dietary pattern analysis: A new direction in nutritional epidemiology. *Curr. Opin. Lipidol.* 2002, 13, 3–9. [CrossRef]

134. Maso, L.D.; La Vecchia, C.; Polesel, J.; Talamini, R.; Levi, F.; Conti, E.; Zambon, P.; Negri, E.; Franceschi, S. Alcohol drinking and overall survival in elderly people. *BMJ* 1995, 311, 1457–1460. [CrossRef] [PubMed]

135. Schulze, M.B.; Hoffmann, K.; Kroke, A.; Boeing, H. Alcoholic disease: Liver and beyond. *Int. J. Cancer* 2004, 109, 277–284. [CrossRef] [PubMed]

136. Trichopoulos, A.; Kouris-Blazos, A.; Wahlqvist, M.L.; Gnardellis, C.; Lagiou, P.; Polychronopoulos, E.; Vassilakou, T.; Lipworth, L.; Trichopoulos, D. Diet and overall survival in elderly people. *BMJ* 1995, 311, 1457–1460. [CrossRef] [PubMed]

137. Grønbaek, M.; Tjønneland, A.; Johansen, D. Type of alcohol and drinking pattern in 56,970 Danish men and women. *Eur. J. Clin. Nutr.* 2000, 54, 174–176. [CrossRef]

138. Biddinger, K.J.; Emdin, C.A.; Haas, M.E.; Wang, M.; Hindy, G.; Ellinor, P.T.; Kalljes, S.; Khera, A.V.; Aragam, K.G. Association of Habitual Alcohol Intake with Risk of Cardiovascular Disease. *JAMA Netw. Open.* 2022, 5, e223849. [CrossRef]

139. Ortola, R.; García-Esquinas, E.; Buño-Soto, A.; Carballo-Casla, A.; Sotos-Prieto, M.; Banegas, J.R.; Rodríguez-Artalejo, F. Alcohol consumption patterns and growth differentiation factor 15 among life-time drinkers aged 65+ years in Spain: A cross-sectional study. *Addiction* 2022, 117, 1647–1657. [CrossRef] [PubMed]

140. Ahmed, A.T.; Karter, A.J.; Werton, E.M.; Doan, J.U.; Weisner, C.M. The relationship between alcohol consumption and glycemic control among patients with diabetes: The Kaiser Permanente Northern California Diabetes Registry. *J. Gen. Intern. Med.* 2008, 23, 275–282. [CrossRef] [PubMed]

141. Hirst, J.A.; Aronson, J.K.; Feakins, B.G.; Ma, C.; Farmer, A.J.; Stevens, R.J. Short- and medium-term effects of light to moderate alcohol intake on glycaemic control in diabetes mellitus: A systematic review and meta-analysis of randomized trials. *Diabet. Med.* 2017, 34, 604–611. [CrossRef] [PubMed]

142. Ahmed, A.T.; Karter, A.J.; Liu, J. Alcohol consumption is inversely associated with adherence to diabetes self-care behaviours. *Diabet. Med.* 2006, 23, 795–802. [CrossRef] [PubMed]

143. Taylor, B.; Rehm, J.; Gmel, G. Moderate alcohol consumption and the gastrointestinal tract. *Dig. Dis.* 2005, 23, 170–176. [CrossRef]

144. Rocco, A.; Compare, D.; Angrisani, D.; Sanduzzi Zamparelli, M.; Nardone, G. Alcoholic disease: Liver and beyond. *World J. Gastroenterol.* 2014, 20, 14652–14659. [CrossRef] [PubMed]

145. Kamper-Jørgensen, M.; Grønbaek, M.; Tolstrup, J.; Becker, U. Alcohol and cirrhosis: Dose–response or threshold effect? *J. Hepatol.* 2004, 41, 25–30. [CrossRef]

146. Ramstedt, M. Per capita alcohol consumption and liver cirrhosis mortality in 14 European countries. *Addiction* 2001, 96 (Suppl. S1), S19–S33. [CrossRef]

147. Singal, A.K.; Bataller, R.; Ahn, J.; Kamath, P.S.; Shah, V.H. ACG Clinical Guideline: Alcoholic Liver Disease. *Am. J. Gastroenterol.* 2018, 113, 175–194. [CrossRef]

148. Jamal, M.M.; Saadi, Z.; Morgan, T.R. Alcohol and hepatitis C. *Dig. Dis.* 2005, 23, 285–296. [CrossRef]

149. Irving, H.M.; Samokhvalov, A.V.; Rehm, J. Alcohol as a risk factor for pancreatitis. A systematic review and meta-analysis. *JOP* 2009, 10, 387–392. [PubMed]

150. Apte, M.V.; Wilson, J.S. Alcohol-induced pancreatic injury. *Best Pract. Res. Clin. Gastroenterol.* 2003, 17, 593–612. [CrossRef]

151. Fuchs, F.D.; Fuchs, S.C. The Effect of Alcohol on Blood Pressure and Hypertension. *Curr. Hypertens Rep.* 2021, 23, 42. [CrossRef] [PubMed]